WHWK
Whitehawk Therapeutics, Inc.
NASDAQ: WHWK · HEALTHCARE · BIOTECHNOLOGY
$4.04
-2.18% today
Updated 2026-04-29
Market cap
$194.92M
P/E ratio
—
P/S ratio
27.28x
EPS (TTM)
$-0.33
Dividend yield
—
52W range
$1 – $4
Volume
0.2M
Whitehawk Therapeutics, Inc. (WHWK) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $749000.00 | $14.58M | $1.12M | $15.22M | $24.35M | $25.98M | $7.14M |
| Revenue growth (YoY) | — | +1846.6% | -92.3% | +1258.6% | +60.1% | +6.7% | -72.5% |
| Cost of revenue | $11.06M | $15.01M | $19.67M | $34.00M | $51.74M | $54.05M | $760000.00 |
| Gross profit | $-10.32M | $-428000.00 | $-18.55M | $-18.78M | $-27.38M | $-28.07M | $6.38M |
| Gross margin | -1377.2% | -2.9% | -1656.3% | -123.4% | -112.4% | -108.0% | 89.4% |
| R&D | $11.06M | $15.01M | $19.67M | $32.66M | $48.93M | $51.03M | $90.96M |
| SG&A | $1.85M | $2.12M | $18.51M | $40.18M | $44.55M | $36.75M | $29.82M |
| Operating income | $-12.17M | $-2.55M | $-111.22M | $-62.68M | $-71.93M | $-67.46M | $-114.40M |
| Operating margin | -1624.8% | -17.5% | -9930.1% | -411.9% | -295.4% | -259.6% | -1601.1% |
| EBITDA | $-12.16M | $-2.54M | $-36.96M | $-58.80M | $-71.76M | $-64.63M | $-114.40M |
| EBITDA margin | -1624.0% | -17.4% | -3299.6% | -386.4% | -294.7% | -248.7% | -1601.1% |
| EBIT | $-12.17M | $-2.55M | $-37.06M | $-58.96M | $-71.93M | $-64.82M | — |
| Interest expense | $83935.00 | $815000.00 | $665000.00 | $230000.00 | $231000.00 | $154000.00 | $0.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-12.26M | $-3.48M | $-110.09M | $-60.51M | $-65.77M | $-63.69M | $-20.60M |
| Net income growth (YoY) | — | +71.6% | -3065.3% | +45.0% | -8.7% | +3.2% | +67.7% |
| Profit margin | -1636.2% | -23.9% | -9829.5% | -397.7% | -270.0% | -245.1% | -288.3% |